Mackenzie Financial Corp Acquires New Shares in TransMedics Group, Inc. (NASDAQ:TMDX)

Mackenzie Financial Corp acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 453,615 shares of the company’s stock, valued at approximately $35,804,000.

Several other hedge funds have also recently bought and sold shares of TMDX. Comerica Bank purchased a new position in TransMedics Group in the 3rd quarter valued at approximately $34,000. Global Retirement Partners LLC acquired a new position in shares of TransMedics Group in the third quarter worth $38,000. Cutler Group LLC CA raised its holdings in shares of TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after acquiring an additional 600 shares during the last quarter. Ancora Advisors LLC acquired a new position in TransMedics Group in the first quarter valued at $38,000. Finally, First Horizon Advisors Inc. increased its stake in TransMedics Group by 45.1% in the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company’s stock valued at $41,000 after purchasing an additional 169 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Trading Down 5.8 %

Shares of NASDAQ TMDX opened at $87.86 on Thursday. The stock’s 50 day moving average price is $83.01 and its two-hundred day moving average price is $72.88. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $68.49 million. During the same period last year, the firm earned ($0.21) EPS. The firm’s revenue was up 158.6% compared to the same quarter last year. As a group, equities research analysts predict that TransMedics Group, Inc. will post -0.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TMDX. Oppenheimer upped their target price on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, February 27th. Piper Sandler began coverage on TransMedics Group in a research note on Thursday, March 28th. They set an “overweight” rating and a $95.00 price target for the company. JPMorgan Chase & Co. upped their price target on TransMedics Group from $87.00 to $105.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Finally, Morgan Stanley upped their price target on TransMedics Group from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $102.00.

Insider Activity at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the sale, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,044,932.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other TransMedics Group news, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $74.01, for a total transaction of $1,110,150.00. Following the completion of the transaction, the chief financial officer now directly owns 23,299 shares of the company’s stock, valued at approximately $1,724,358.99. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Waleed H. Hassanein sold 12,000 shares of the stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at $7,044,932.83. The disclosure for this sale can be found here. Insiders have sold a total of 115,408 shares of company stock worth $9,802,401 in the last three months. 6.70% of the stock is owned by company insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.